298
- Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, et al. A
pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal
antibody to alpha-4 integrin. Aliment Pharmacol Ther. 2002;16(4):699–705. - Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive
multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med.
2005;353(4):362–8. - Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy compli-
cating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med.
2005;353(4):369–74. - Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leuko-
encephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375–81. - Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, et al. Natalizumab and
progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?
Arch Neurol. 2010;67(8):923–30. - Aksamit AJ. Progressive multifocal leukoencephalopathy. Curr Treat Options Neurol.
2008;10(3):178–85. - Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencepha-
lopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis
Rheum. 2007;56(7):2116–28. - Singh S, Kumar N, Loftus EV Jr, Kane SV. Neurologic complications in patients with inflam-
matory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis.
2013;19(4):864–72. - Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, et al. Prevalence of poly-
omavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis.
2009;199(6):837–46. - Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med.
2012;366(20):1870–80. - Avasarala J. The TOUCH program and natalizumab: fundamental flaw in patient protection.
F1000Res. 2015;4:1450. - Foley J. Recommendations for the selection, treatment, and management of patients utilizing
natalizumab therapy for multiple sclerosis. Am J Manag Care. 2010;16(6 Suppl):S178–83. - Juillerat P, Wasan SK, Fowler SA, Friedman S, Pabby VK, Coukas JA, et al. Efficacy and
safety of natalizumab in Crohn’s disease patients treated at 6 Boston academic hospitals.
Inflamm Bowel Dis. 2013;19(11):2457–63. - Kane SV, Horst S, Sandborn WJ, Becker B, Neis B, Moscandrew M, et al. Natalizumab for
moderate to severe Crohn’s disease in clinical practice: the Mayo Clinic Rochester experience.
Inflamm Bowel Dis. 2012;18(12):2203–8. - Sugiura T, Kageyama S, Andou A, Miyazawa T, Ejima C, Nakayama A, et al. Oral treatment
with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of
experimental colitis in mice. J Crohns Colitis. 2013;7(11):e533–42. - Yoshimura N, Watanabe M, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, et al. Safety and
efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients
with active ulcerative colitis. Gastroenterology. 2015;149(7):1775–83.e2. - Fedyk ER, Wyant T, Yang LL, Csizmadia V, Burke K, Yang H, et al. Exclusive antagonism
of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in
primates. Inflamm Bowel Dis. 2012;18(11):2107–19. - Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selec-
tive antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in develop-
ment for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864–75. - Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment
of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med.
2005;352(24):2499–507.
J.K. Limdi and F.A. Farraye